

## Supplementary Appendix

The author has provided this appendix containing additional information about her work.

Supplement to: Cadwallader AB. Why should clinicians care about global medical supply chain security? *AMA J Ethics*. 2024;26(4):277-281. doi: 10.1001/amajethics.2024.277.

### Table of Contents

Page 2: **Published Sources on Supply Chains for Medical Products**

## Published Sources on Supply Chains for Medical Products

1. Alper J; National Academies of Sciences, Engineering, and Medicine. *Continuous Manufacturing for the Modernization of Pharmaceutical Production: Proceedings of a Workshop*. National Academies Press; 2019.
2. Ellis S. Supply chain agility in the pharmaceutical industry. International Data Corporation; 2020. Accessed February 23, 2024. <https://go.tracelink.com/rs/776-BAW-230/images/IDC%20whitepaper.pdf>
3. Hastings Roer E, Globus-Harris I. A mechanism to reduce medical supply shortfalls during pandemics. RAND Corporation; 2020. Accessed February 23, 2024. [https://www.rand.org/content/dam/rand/pubs/perspectives/PEA100/PEA187-1/RAND\\_PEA187-1.pdf](https://www.rand.org/content/dam/rand/pubs/perspectives/PEA100/PEA187-1/RAND_PEA187-1.pdf)
4. Mahmoodi F, Blutinger E, Echazú L, Nocetti D. COVID-19 and the health care supply chain: impacts and lessons learned. *Supply Chain Xchange*. February 17, 2021. Accessed February 23, 2024. <https://www.thescxchange.com/articles/4417-covid-19-and-the-health-care-supply-chain-impacts-and-lessons-learned>
5. COVID-19, advanced pharmaceutical manufacturing, and the US supply chain. Federation of American Scientists blog. June 17, 2021. Accessed August 10, 2022. <https://fas.org/blogs/sciencepolicy/covid-19-advanced-pharmaceutical-manufacturing-and-the-u-s-supply-chain/>
6. Cecire MH, Bodie A, Gottron F, et al. COVID-19 and domestic PPE production and distribution: issues and policy options. Congressional Research Service; 2020. Accessed February 23, 2024. <https://crsreports.congress.gov/product/pdf/R/R46628>
7. Chen PG, Chan EW, Qureshi N, Shelton S, Mulcahy AW; RAND Health Care. *Medical Device Supply Chains: An Overview and Description of Challenges During the COVID-19 Pandemic*. US Department of Health and Human Services; 2021. Accessed February 23, 2024. <https://aspe.hhs.gov/sites/default/files/documents/688790e106210d6434ddee5907b0b38/pr-a328-2-devices-supply-chain.pdf>
8. Center for Drug Evaluation and Research. Quality Management maturity: essential for stable US supply chains of quality pharmaceuticals, US Food and Drug Administration; 2022. Accessed April 5, 2022. <https://www.fda.gov/media/157432/download>
9. Stark D, Zweig O, Rura S, Modi A, Krumbüller F, Evans J. Pharma supply chains of the future. Ernst & Young; 2022. Accessed July 28, 2022. [https://assets.ey.com/content/dam/ey-sites/ey-com/en\\_gl/topics/life-sciences/life-sciences-pdfs/ey-pharma-supply-chains-of-the-future-final.pdf](https://assets.ey.com/content/dam/ey-sites/ey-com/en_gl/topics/life-sciences/life-sciences-pdfs/ey-pharma-supply-chains-of-the-future-final.pdf)
10. Cohen J, Rodgers YVM. Contributing factors to personal protective equipment shortages during the COVID-19 pandemic. *Prevent Med*. 2020;141:106263.
11. Increasing transparency in the medicines supply chain. United States Pharmacopeia; 2020. Accessed February 23, 2024. <https://www.usp.org/sites/default/files/usp/document/about/public-policy/supply-chain-transparency.pdf>
12. Centers for Disease Control and Prevention. COVID-19: U.S. Impact on Antimicrobial Resistance US Department of Health and Human Services; 2022. Accessed July 29, 2022. <https://www.cdc.gov/drugresistance/pdf/covid19-impact-report-508.pdf>
13. National Academies of Sciences, Engineering, Medicine, Health, Medicine. *Stronger Food and Drug Regulatory Systems Abroad (2020)*. In: Washington (DC): National Academies Press (US) Copyright 2019 by the National Academy of Sciences. All rights reserved.; 2020.
14. Kilpatrick J, Barter L. *COVID-19: Managing Supply Chain Risk and Disruption*. Deloitte; 2020.
15. Bhaskar S, Tan J, Bogers MLAM, et al. At the epicenter of COVID-19—the tragic failure of the global supply chain for medical supplies. *Front Public Health*. 2020;8:562882.
16. Schondelmeyer SW, Seifert J, Margraf DJ, et al. COVID-19: the CIDRAP viewpoint. Part 6: Ensuring a Resilient US Prescription Drug Supply. CIDRAP; 2020. Accessed February 23,

2024. <https://www.cidrap.umn.edu/sites/default/files/downloads/cidrap-covid19-viewpoint-part6.pdf>
17. MSD; Avalere Health. *COVID-19 Global Regulatory Agilities: Report of Multi-Stakeholder Virtual Workshop*. MSD; 2022. Accessed February 23, 2024. <https://www.msd.com/wp-content/uploads/sites/9/2022/06/COVID-19-Global-Regulatory-Agilities.pdf>
  18. Reh G, Ronte H. Securing trust in the global COVID-19 supply chain. Deloitte; 2020. Accessed July 27, 2022. <https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-future-of-trust.pdf>
  19. Rastogi S, Sharma SK, Chauhan J, et al. Pharmacopoeia roles and responses: a systemic resilience approach to COVID-19 pandemic. *Saudi Pharm J*. 2022;30(5):613-618.
  20. Jacoby R, Heim M, Fernandez Preda C. The first 90 days: US biopharmaceutical finished goods supply chain response to COVID-19. Deloitte; HDA Research Foundation; 2020. Accessed February 23, 2024. <https://www2.deloitte.com/content/dam/Deloitte/us/Documents/life-sciences-health-care/us-lshc-biopharmaceutical-finished-goods-supply-chain-response-to-COVID-19.pdf>
  21. Crowley J, Rogers M, Anupindi R, et al. Reimagining the global supply chain post COVID-19. Principal to Principal; 2021. Accessed February 23, 2024. <https://www.amacad.org/sites/default/files/publication/downloads/%28Megan%20Ranney%29%20P2P%20Supply%20Chain%20Report%20-%20FINAL%20MAY%202021.pdf>
  22. Spieske A, Gebhardt M, Kopyto M, Birkel H. Improving resilience of the healthcare supply chain in a pandemic: evidence from Europe during the COVID-19 crisis. *J Purchasing Supply Manage*. 2022;28(5):100748.
  23. Key elements to building a more resilient supply chain. United States Pharmacopeia. Accessed June 23, 2022. <https://www.usp.org/sites/default/files/usp/document/our-impact/covid-19/global-policy-supply-chain.pdf>
  24. Aulanger G, Badia-Tahull M, Burry L, et al. Confronting the fragility of medicine supply chains. Economist Group; 2021. Accessed July 27, 2022. [https://impact.economist.com/perspectives/sites/default/files/ei202\\_-\\_fragile\\_supply\\_chains\\_-\\_dv6.pdf](https://impact.economist.com/perspectives/sites/default/files/ei202_-_fragile_supply_chains_-_dv6.pdf)
  25. Urah SK, Coukell A, Jungman E, et al. Drug shortages: an exploration of the relationship between US market forces and sterile injectable pharmaceutical products: interviews with 10 pharmaceutical companies. Pew Charitable Trusts; International Society for Pharmaceutical Engineering. 2017. Accessed February 23, 2024. [https://www.pewtrusts.org/-/media/assets/2017/01/drug\\_shortages.pdf](https://www.pewtrusts.org/-/media/assets/2017/01/drug_shortages.pdf)
  26. Cueni TB. COVID-19 lessons and solutions to create a healthier, safer and more equitable world. *J Infect Dis*. 2022;10(6):1000518.
  27. American Medical Association; American Society of Anesthesiologists; American Society of Health-System Pharmacists; Association for Clinical Oncology; United States Pharmacopeia. Improving the quality and resilience of the United States healthcare supply chain American Society of Health-System Pharmacists; 2021. Accessed February 26, 2024. <https://www.ashp.org/-/media/assets/news-and-media/docs/Healthcare-Supply-Chain-Recommendations#:~:text=Improve%20multinational%20cooperation%20on%20supply,but%20not%20limited%20to%20foreign>
  28. Smith R. Ensuring flexible and resilient supply chains. Pfizer. Accessed August 10, 2022. <https://www.pfizerpolicy.eu/article/ensuring-flexible-and-resilient-supply-chains>
  29. Drug Shortages Task Force. *Drug Shortages: Root Causes and Potential Solutions*. US Food and Drug Administration; 2019. Updated February 21, 2020. Accessed March 10, 2020. <https://www.fda.gov/media/131130/download>
  30. JSI Research & Training Institute. Supply chain management for healthcare in humanitarian response settings. USAID: United States Agency for International Development; 2020.

- Accessed August 12, 2022.  
[https://publications.jsi.com/JSIInternet/Inc/Common/download\\_pub.cfm?id=24459&lid=3](https://publications.jsi.com/JSIInternet/Inc/Common/download_pub.cfm?id=24459&lid=3)
31. A 5-point plan for reinventing the pharma supply chain. GEP. Accessed August 12, 2022.  
<https://www.gep.com/white-papers/a-5-point-plan-for-reinventing-the-pharma-supply-chain>
  32. Medicine shortages in the EU: causes and solutions. European Parliament. July 16, 2020. Updated September 30, 2022. Accessed August 12, 2022.  
<https://www.europarl.europa.eu/news/en/headlines/society/20200709ST083006/medicine-shortages-in-the-eu-causes-and-solutions>
  33. Handfield R, Finkenstadt DJ, Schneller ES, Godfrey AB, Guinto P. A commons for a supply chain in the post-COVID-19 era: the case for a reformed strategic national stockpile. *Milbank Q.* 2020;98(4):1058-1090.
  34. Årdal C, Baraldi E, Beyer P, et al. Supply chain transparency and the availability of essential medicines. *Bull World Health Organ.* 2021;99(4):319-320.
  35. Sardella A. The US active pharmaceutical ingredient infrastructure: the current state and considerations to increase US healthcare security. Center for Analytics and Business Insights, Washington University; 2021. Accessed May, 2022.  
<https://wustl.app.box.com/s/rjo1i7yews99hdr8zeo5fp0u71g47m0i>
  36. Socal MP, Sharfstein JM, Greene JA. The pandemic and the supply chain: gaps in pharmaceutical production and distribution. *Am J Public Health.* 2021;111(4):635-639.
  37. Chapman S, Dedet G, Lopert R. Shortages of medicines in OECD countries. *OECD Health Working Pap.* 2022;137.
  38. Lal A, Lim C, Almeida G, Fitzgerald J. Minimizing COVID-19 disruption: ensuring the supply of essential health products for health emergencies and routine health services. *Lancet Reg Health Am.* 2022;6:100129.
  39. Lee SK, Mahl SK, Rowe BH, Lexchin J. Pharmaceutical security for Canada. *CMAJ.* 2022;194(32):E1113-E1116.
  40. Mattingly TJ 2nd, Conti RM. Ensuring a high-quality and resilient supply chain of essential medications means paying more. *J Manag Care Spec Pharm.* 2022;28(5):573-576.
  41. US Department of Homeland Security. Supply chain resilience guide. US Department of Homeland Security; 2019. Accessed August 11, 2022.  
<https://www.fema.gov/sites/default/files/2020-07/supply-chain-resilience-guide.pdf>
  42. DiEuliis D, Terrell P. Taking stock of the national stockpile: modernizing for a dynamic response. Institute for National Strategic Studies, National Defense University. August 18, 2021. Accessed August 11, 2022.  
<https://inss.ndu.edu/Media/News/Article/2736769/taking-stock-of-the-national-stockpile-modernizing-for-a-dynamic-response/>
  43. Conti RM, Morton FS. Building a resilient Rx drug supply: a new HHS office and other steps. *Health Affairs Forefront.* August 27, 2021. Accessed August 10, 2022.  
<https://www.healthaffairs.org/doi/10.1377/forefront.20210824.559824/>
  44. Partnering with the healthcare supply chain during disasters. TRACIE: Healthcare Emergency Preparedness Information Gateway. December 2022. Accessed February 26, 2024.  
<https://files.asprtracie.hhs.gov/documents/aspr-tracie-partnering-with-the-healthcare-supply-chain-during-disasters.pdf>
  45. Iakovou E, White CC 3rd. How to build more secure, resilient, next-gen US supply chains. Brookings. December 3, 2020. Accessed August 10, 2022.  
<https://www.brookings.edu/techstream/how-to-build-more-secure-resilient-next-gen-u-s-supply-chains/>
  46. Broadbent M. Covid-19 demand shock and preparedness response—securing medical supply chains: the trusted trade partner network. Center for Strategic and International Studies; 2020. Accessed August 11, 2022. [https://csis-website-prod.s3.amazonaws.com/s3fs-public/publication/201221\\_Broadbent\\_Covid19\\_Shock.pdf](https://csis-website-prod.s3.amazonaws.com/s3fs-public/publication/201221_Broadbent_Covid19_Shock.pdf)

47. Sardella A, De Bona P. Safeguarding the United States pharmaceutical supply chain and policy considerations to mitigate shortages of essential medicines. Washington University in St. Louis; 2021. Accessed August 12, 2022. <https://wustl.app.box.com/s/wpqr6704f02eywivqsz7h1vfn8seb848>
48. Building resilient pharma supply chains. Kearney. February 23, 2022. Accessed August 10, 2022. <https://www.kenney.com/health/article/-/insights/three-ways-to-build-resilience-into-pharmaceutical-supply-chains>
49. Administration for Strategic Preparedness and Response. Public health supply chain and industrial base: one-year report in response to Executive Order 14017. US Department of Health and Human Services; 2022. Accessed August 15, 2022. <https://aspr.hhs.gov/MCM/IBx/2022Report/Documents/Public-Health-Supply-Chain-and-Industrial-Base%20One-Year-Report-Feb2022.pdf>
50. Husted DL. Business continuity planning to prevent drug shortages. January/February 2021. ISPE. Accessed August 12, 2022. [https://ispe.org/pharmaceutical-engineering/january-february-2021/business-continuity-planning-prevent-drug#footnote1\\_f9dtx1f](https://ispe.org/pharmaceutical-engineering/january-february-2021/business-continuity-planning-prevent-drug#footnote1_f9dtx1f)
51. US Department of Defense; US Department of Homeland Security; US Department of Health and Human Services; US Department of Veterans Affairs. National strategy for a resilient public health supply chain. Administration for Strategic Preparedness and Response; 2021. Accessed August 10, 2022. <https://www.phe.gov/Preparedness/legal/Documents/National-Strategy-for-Resilient-Public-Health-Supply-Chain.pdf>
52. FAQs: the pandemic fund. World Bank. June 30, 2022. Accessed July 29, 2022. [https://www.worldbank.org/en/topic/pandemics/brief/factsheet-financial-intermediary-fund-for-pandemic-prevention-preparedness-and-response#:~:text=Pandemic%20preparedness%20is%20a%20top,\)%20on%20June%2030%2C%202022](https://www.worldbank.org/en/topic/pandemics/brief/factsheet-financial-intermediary-fund-for-pandemic-prevention-preparedness-and-response#:~:text=Pandemic%20preparedness%20is%20a%20top,)%20on%20June%2030%2C%202022)
53. McDonnell A, Pisani E, Singhvi S, Chalkidou K, Yadav P. A path to resiliency: mitigating the impacts of COVID-19 on essential medicines supply chains. Center for Global Development; 2021. CGD policy paper 213. Accessed August 10, 2022. [https://www.cgdev.org/sites/default/files/Mitigating-impact-covid-essential-medicine-supply-chain\\_0.pdf](https://www.cgdev.org/sites/default/files/Mitigating-impact-covid-essential-medicine-supply-chain_0.pdf)
54. *Hearing Before the Subcommittee on Homeland Security and Governmental Affairs, 117th Cong, 1st Sess (2021)* (testimony of Stephen W. Schondelmeyer, PhD, director, PRIME Institute, University of Minnesota). Accessed August 11, 2022. <https://www.hsgac.senate.gov/imo/media/doc/Testimony-Schondelmeyer-2021-05-19-11.pdf>
55. Association for Accessible Medicines. The Association for Accessible Medicines' expanded advocacy strategy to further enhance the security of the US pharmaceutical supply chain. Association for Accessible Medicines; 2021. Accessed August 11, 2022. <https://accessiblemeds.org/sites/default/files/2021-05/AAM-Blueprint-Update.pdf>
56. Lesmeister F, Kwasniok T, Peters D. A strategy to make pharma supply chains more resilient. Bain & Company. November 19, 2020. Accessed August 10, 2022. <https://www.bain.com/insights/a-strategy-to-make-pharma-supply-chains-more-resilient/>
57. A pharmaceutical strategy for Europe. European Commission. November 25, 2020. Accessed August 3, 2022. [https://health.ec.europa.eu/medicinal-products/pharmaceutical-strategy-europe\\_en](https://health.ec.europa.eu/medicinal-products/pharmaceutical-strategy-europe_en)
58. Choe J, Crane M, Greene J, et al. The pandemic and the supply chain: addressing gaps in pharmaceutical production and distribution. Johns Hopkins Bloomberg School of Public Health; 2020. Accessed August 10, 2022. [https://www.jhsph.edu/research/affiliated-programs/johns-hopkins-drug-access-and-affordability-initiative/publications/Pandemic\\_Supply\\_Chain.pdf](https://www.jhsph.edu/research/affiliated-programs/johns-hopkins-drug-access-and-affordability-initiative/publications/Pandemic_Supply_Chain.pdf)

59. Association for Accessible Medicines. A blueprint for enhancing the security of the US pharmaceutical supply chain. Association for Accessible Medicines. October 2021. Accessed August 11, 2022. <https://accessiblemeds.org/sites/default/files/2020-04/AAM-Blueprint-US-Pharma-Supply-Chain.pdf>
60. Green VR, Dabrowska A, Costin KM. FDA's role in the medical product supply chain and considerations during COVID-19. Congressional Research Service; 2020. Accessed August 11, 2022. <https://crsreports.congress.gov/product/pdf/R/R46507>
61. Inspector General. Evaluation of the Department of Defense's mitigation of foreign suppliers in the pharmaceutical supply chain. US Department of Defense; 2021. Accessed August 11, 2022. [https://media.defense.gov/2021/Sep/22/2002859154/-1/-1/1/DODIG-2021-126\\_REDACTED.PDF](https://media.defense.gov/2021/Sep/22/2002859154/-1/-1/1/DODIG-2021-126_REDACTED.PDF)
62. Foster T, Patel P, Skiba K. Four ways pharma companies can make their supply chains more resilient. McKinsey & Company. September 23, 2021. Accessed August 8, 2022. <https://www.mckinsey.com/industries/life-sciences/our-insights/four-ways-pharma-companies-can-make-their-supply-chains-more-resilient>